Qrons Inc.: Qrons Announces a New Pre-Clinical Research Prog

Qrons Inc.: Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200 Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and

NEW YORK, NY / ACCESSWIRE / December 14, 2022 / Qrons Inc. (OTCQB:QRON) announced today that it formed a collaboration with scientists at one of the largest public research universities in Israel, by which

Related Keywords

Israel , New York , United States , Ido Merfeld , Kostenloser Wertpapierhandel , Jonah Meer , Material Research Center , Institute For Translational Research , Qrons Inc View , Qrons Inc , Ariel University Board Of Directors , Ariel University , Ariel Scientific Innovation Ltd , Traumatic Brain Injuries , Ido Merfeld President , Molecular Biology , New York City , Translational Research , Compact Accelerators , Radiation Sources , Qrons , Nnounces , Linical , Research , Program , Pest , Efficacy , Tellurium , Ased , Compounds , Combination , Ns200 , Product , Candidate , Independently , Reating , Diffused , Axonal , Injuries , Ntibiotic , Resistant ,